Download PDF
Semin Liver Dis 2024; 44(03): 287-299
DOI: 10.1055/s-0044-1788277
Review Article

Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease

Authors

  • Monica A. Tincopa

    1   Division of Gastroenterology and Hepatology, MASLD Research Center, University of California at San Diego, La Jolla, California

  • Rohit Loomba

    1   Division of Gastroenterology and Hepatology, MASLD Research Center, University of California at San Diego, La Jolla, California
    2   School of Public Health, University of California at San Diego, La Jolla, California

Funding R.L. receives funding support from NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, P30DK120515), NHLBI (P01HL147835), and John C. Martin Foundation (RP124).
Further Information
   Permissions and Reprints


Graphical Abstract

Preview

Abstract

Risk of disease progression and clinical outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with fibrosis stage and presence of “at-risk metabolic dysfunction-associated steatohepatitis (MASH).” Although liver biopsy is considered the gold standard to diagnose MASH and stage of fibrosis, biopsy is infrequently performed in clinical practice and has associated sampling error, lack of interrater reliability, and risk for procedural complications. Noninvasive tests (NITs) are routinely used in clinical practice for risk stratification of patients with MASLD. Several NITs are being developed for detecting “at-risk MASH” and cirrhosis. Clinical care guidelines apply NITs to identify patients needing subspecialty referral. With recently approved Food and Drug Administration treatment for MASH and additional emerging pharmacotherapy, NITs will identify patients who will most benefit from treatment, monitor treatment response, and assess risk for long-term clinical outcomes. In this review, we examine the performance of NITs to detect “at-risk MASH,” fibrosis stage, response to treatment, and risk of clinical outcomes in MASLD and MASH.

Keywords

NAFLD - MASLD - MASH - noninvasive tests


Publication History

Article published online:
09 July 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA